DK3828204T3 - Fusionsproteiner af humane proteinfragmenter til at skabe ordnede multimeriserede immunoglobulin-FC-sammensætninger med forbedret komplementbinding - Google Patents

Fusionsproteiner af humane proteinfragmenter til at skabe ordnede multimeriserede immunoglobulin-FC-sammensætninger med forbedret komplementbinding

Info

Publication number
DK3828204T3
DK3828204T3 DK20207511.5T DK20207511T DK3828204T3 DK 3828204 T3 DK3828204 T3 DK 3828204T3 DK 20207511 T DK20207511 T DK 20207511T DK 3828204 T3 DK3828204 T3 DK 3828204T3
Authority
DK
Denmark
Prior art keywords
compositions
fusion proteins
human protein
protein fragments
complement binding
Prior art date
Application number
DK20207511.5T
Other languages
English (en)
Inventor
David S Block
Henrik Olsen
Original Assignee
Gliknik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57885189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3828204(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gliknik Inc filed Critical Gliknik Inc
Application granted granted Critical
Publication of DK3828204T3 publication Critical patent/DK3828204T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
DK20207511.5T 2015-07-24 2016-07-22 Fusionsproteiner af humane proteinfragmenter til at skabe ordnede multimeriserede immunoglobulin-FC-sammensætninger med forbedret komplementbinding DK3828204T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562196478P 2015-07-24 2015-07-24
EP16831166.0A EP3325011B3 (en) 2015-07-24 2016-07-22 Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding

Publications (1)

Publication Number Publication Date
DK3828204T3 true DK3828204T3 (da) 2026-01-19

Family

ID=57885189

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20207511.5T DK3828204T3 (da) 2015-07-24 2016-07-22 Fusionsproteiner af humane proteinfragmenter til at skabe ordnede multimeriserede immunoglobulin-FC-sammensætninger med forbedret komplementbinding
DK16831166.0T DK3325011T6 (da) 2015-07-24 2016-07-22 Fusionsproteiner af humane proteinfragmenter til fremstilling af ordnede multimeriserede immunoglobulin Fc-sammensætninger med forstærket komplementbinding

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16831166.0T DK3325011T6 (da) 2015-07-24 2016-07-22 Fusionsproteiner af humane proteinfragmenter til fremstilling af ordnede multimeriserede immunoglobulin Fc-sammensætninger med forstærket komplementbinding

Country Status (22)

Country Link
US (2) US12122836B2 (da)
EP (3) EP3828204B1 (da)
JP (2) JP6937737B2 (da)
KR (3) KR102649702B1 (da)
CN (2) CN107847599B (da)
AU (3) AU2016297862C1 (da)
CA (1) CA2991254A1 (da)
CY (1) CY1123719T1 (da)
DK (2) DK3828204T3 (da)
ES (2) ES2846024T7 (da)
FI (1) FI3325011T6 (da)
HU (1) HUE053062T2 (da)
IL (3) IL314842A (da)
LT (1) LT3325011T (da)
MX (2) MX394116B (da)
PL (2) PL3325011T6 (da)
PT (2) PT3828204T (da)
RU (1) RU2737378C2 (da)
SI (1) SI3325011T1 (da)
TW (2) TWI729993B (da)
WO (1) WO2017019565A2 (da)
ZA (1) ZA202105055B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543257A1 (en) 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
SG11201900427PA (en) 2016-07-22 2019-02-27 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
IL266988B2 (en) * 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER
JP7351835B2 (ja) 2017-12-14 2023-09-27 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
EP4130032A4 (en) * 2020-03-26 2024-03-13 Denka Company Limited Reagent containing antibody having partial deletion of fc region
AU2021278819A1 (en) * 2020-05-05 2022-11-24 Annexon, Inc. Compositions and methods for treating epilepsy
CN116113434A (zh) * 2020-05-20 2023-05-12 酵活生物制药有限公司 对Fc γ RIIB具有选择性的异二聚体Fc变体
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN114478741B (zh) * 2021-12-31 2023-03-07 苏州大学 contactin 6蛋白突变体及其编码基因、表达载体与应用
CN115028738B (zh) * 2022-06-14 2025-05-16 天津医科大学 一种Fc融合蛋白双重靶向降解剂及应用

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US6004781A (en) 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5681566A (en) 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
IL102915A (en) 1992-01-19 2005-12-18 Yeda Res & Dev Soluble ldl receptor and its preparation
EP0664710A4 (en) 1992-08-07 1998-09-30 Progenics Pharm Inc IMMUNOCONJUGATES COMPOSED OF A NON-PEPTIDYLENE PART AND A CD4-GAMMA2 OR CD4-IgG2 PART AND USES THEREOF.
CA2153661A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3871099A (en) 1998-05-06 1999-11-23 Temple University - Of The Commonwealth System Of Higher Education Reversal of proinflammatory response by ligating the macrophage fcgammari receptor
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE360031T1 (de) 2000-01-03 2007-05-15 Tr Associates L L C Chimäre proteine und anwendungen
WO2002055992A2 (en) 2001-01-12 2002-07-18 Becton Dickinson Co Intrinsically fluorescent, self-multimerizing mhc fusion proteins and complexes thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
HUP0303428A2 (hu) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
AU2002250293B2 (en) 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
AU2002315052A1 (en) 2001-05-15 2002-11-25 Emory University Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7094306B2 (en) 2001-12-18 2006-08-22 Dow Corning Toray Silicone Co., Ltd. Photocurable organic polymer composition
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP1542721A4 (en) 2002-06-14 2007-05-02 Centocor Inc MODIFIED "S" ANTIBODIES
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
DK1606318T3 (da) 2003-03-26 2009-11-02 Apogenix Gmbh Forbedrede Fc-fusionsproteiner
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US20150071948A1 (en) * 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
EP1691832A2 (en) 2003-09-29 2006-08-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunoglobulins whith potent and broad antiviral activity
WO2005047337A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005089503A2 (en) 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
WO2006008739A2 (en) 2004-07-19 2006-01-26 Elutex Ltd. Modified conductive surfaces having active substances attached thereto
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
EP1824979A2 (en) 2004-12-10 2007-08-29 Trigen GmbH Methods, products and uses involving platelets and/or the vasculature
WO2006113889A2 (en) 2005-04-19 2006-10-26 University Of Maryland Compositions and methods for modulating interleukin-10
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PT1928910E (pt) 2005-08-16 2014-03-06 Hanmi Science Co Ltd Um método para produção em massa de uma região fc da imunoglobulina com deleção dos resíduos de metionina inicial
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
EP1991578A2 (en) 2006-02-17 2008-11-19 Rappaport Family Institute For Research in the Medical Sciences Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
EP2006305B1 (en) 2006-03-03 2016-08-10 The Chemo-Sero-Therapeutic Research Institute Modified antibody with enhanced bioactivity
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
WO2008114011A2 (en) 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
RS53302B (sr) 2007-05-11 2014-08-29 Alexion Pharma Holding Alkalna fosfataza koja je usmerena na kosti, pribor i postupci upotrebe
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
CN103897063B (zh) 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
EP2158210B1 (en) 2007-06-14 2015-12-09 Galactica Pharmaceuticals, Inc. Rage fusion proteins
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
WO2009079242A2 (en) 2007-12-05 2009-06-25 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
WO2010065578A2 (en) 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
BRPI1006998A2 (pt) 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
GB0922209D0 (en) 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
WO2011091078A2 (en) * 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CA2805024A1 (en) 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiples sclerosis, rheumatoid arthritis and other autoimmune disorders
EP3543257A1 (en) * 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
AU2015200330B2 (en) 2010-07-28 2016-10-27 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
PL2635607T3 (pl) * 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2822366A1 (en) * 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
US20140370012A1 (en) 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
AU2013229786B2 (en) * 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
EP2905290B1 (en) * 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
AU2012392760C1 (en) 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
AU2013372331A1 (en) 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
EP3114137A1 (en) 2014-03-05 2017-01-11 UCB Biopharma SPRL Multimeric fc proteins
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
EP3131926A1 (en) 2014-04-16 2017-02-22 UCB Biopharma SPRL Multimeric fc proteins
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
GB201412821D0 (en) 2014-07-18 2014-09-03 Liverpool School Tropical Medicine Polymeric proteins and uses thereof
WO2016073917A1 (en) 2014-11-06 2016-05-12 Gliknik Inc. Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose
WO2016139365A1 (en) 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
GB201515745D0 (en) 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
SG11201900427PA (en) 2016-07-22 2019-02-27 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds

Also Published As

Publication number Publication date
SI3325011T1 (sl) 2021-02-26
RU2018106332A3 (da) 2019-11-13
KR102794242B1 (ko) 2025-04-11
CN107847599A (zh) 2018-03-27
EP3828204A1 (en) 2021-06-02
HK1254447A1 (en) 2019-07-19
IL314842A (en) 2024-10-01
AU2025205063A1 (en) 2025-09-11
EP3325011B3 (en) 2023-03-15
TWI812951B (zh) 2023-08-21
US20180244772A1 (en) 2018-08-30
IL309260B2 (en) 2025-01-01
JP7122440B2 (ja) 2022-08-19
TW202134433A (zh) 2021-09-16
AU2016297862A1 (en) 2018-02-01
CN107847599B (zh) 2022-10-04
EP4696378A3 (en) 2026-05-06
HUE053062T2 (hu) 2021-06-28
RU2018106332A (ru) 2019-08-26
IL256879B2 (en) 2024-05-01
EP3325011A2 (en) 2018-05-30
CN116063510A (zh) 2023-05-05
EP3828204B1 (en) 2025-10-22
US20250011433A1 (en) 2025-01-09
AU2016297862B2 (en) 2022-06-09
JP2018528167A (ja) 2018-09-27
TWI729993B (zh) 2021-06-11
NZ738949A (en) 2024-12-20
AU2022224791B2 (en) 2025-04-10
DK3325011T6 (da) 2023-05-15
KR20250053203A (ko) 2025-04-21
PT3828204T (pt) 2026-01-20
MX2022008337A (es) 2022-08-04
DK3325011T3 (da) 2020-12-14
RU2737378C2 (ru) 2020-11-27
MX394116B (es) 2025-03-19
EP3325011A4 (en) 2019-03-13
KR20180031676A (ko) 2018-03-28
AU2022224791A1 (en) 2022-10-06
CY1123719T1 (el) 2022-05-27
PL3325011T3 (pl) 2021-05-17
EP4696378A2 (en) 2026-02-18
JP2021167325A (ja) 2021-10-21
ES2846024T3 (es) 2021-07-28
MX2018000587A (es) 2018-05-02
JP6937737B2 (ja) 2021-09-22
IL256879A (en) 2018-03-29
EP3325011B1 (en) 2020-11-18
IL309260B1 (en) 2024-09-01
KR20240042137A (ko) 2024-04-01
LT3325011T (lt) 2021-01-25
BR112017028550A2 (pt) 2018-09-04
PL3325011T6 (pl) 2023-06-26
US12122836B2 (en) 2024-10-22
IL256879B1 (en) 2024-01-01
PT3325011T (pt) 2021-01-27
CA2991254A1 (en) 2017-02-02
RU2020138007A (ru) 2020-12-17
WO2017019565A3 (en) 2017-03-09
IL309260A (en) 2024-02-01
FI3325011T6 (fi) 2023-05-11
KR102649702B1 (ko) 2024-03-21
ES2846024T7 (es) 2023-06-22
TW201713697A (zh) 2017-04-16
WO2017019565A2 (en) 2017-02-02
AU2016297862C1 (en) 2022-12-15
ZA202105055B (en) 2024-07-31
PL3828204T3 (pl) 2026-03-30
ES3060140T3 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
DK3325011T3 (da) Fusionsproteiner af humane proteinfragmenter til fremstilling af ordnede multimeriserede immunoglobulin Fc-sammensætninger med forstærket komplementbinding
DK3604527T3 (da) Anvendelse af programmerbare dna-bindingsproteiner til at forbedre målrettet genommodifikation
IL268895A (en) Compositions and methods for inhibition of lineage specific proteins
DK3298033T4 (da) Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
EP3461261A4 (en) CD3 BINDING PROTEINS WITH UNIVERSAL VARIABLE FRAGMENT
IL256785A (en) Chimeric polypeptide assembly and methods of making and using the same
DK3137504T3 (da) Antistofbinding til fcrn til behandling af autoimmunsygdomme
DK3292141T3 (da) Fusionsproteiner
DK3303317T3 (da) Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner
PL3322734T3 (pl) Wielowartościowe i wielospecyficzne białka fuzyjne wiążące się z DR5
DK3389636T3 (da) Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler
EP3433269C0 (en) PD-1 AND 4-1 BB FUSION PROTEINS
DK3199179T3 (da) Formulering af rekombinant fusionsprotein
IL257302B (en) Apoa-1 fusion polypeptides and related compositions and methods
DK3350334T3 (da) Udtryk af rekombinante proteiner i trichoplusia ni pupper
EP3344278A4 (en) INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
MA56416A (fr) Détermination de la pureté de protéines multimériques
EP3738976C0 (en) IL-17A-BINDING FUSION PROTEIN
IL264257A (en) Fusion proteins of human protein fragments to create ordered multimeric fc immunoglobulin preparations with improved fc receptor binding
DK3380119T3 (da) Fmdv- og e2-fusionsproteiner og anvendelser deraf
EP3464384A4 (en) FUSION PRODUCT CONSTRUCT
DK3149163T3 (da) Prohæmostatiske proteiner til behandling af blødning
DK3466978T3 (da) Fusionsprotein til forbedring af proteinekspression fra mål-mRNA
HK40001143A (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
GB201522314D0 (en) Latency associated protein construct for providing latency to TNFR2-immunoglobulin fusion proteins